Who makes HEXOCYCLIUM?

HEXOCYCLIUM is developed by AbbVie.

What development phase is HEXOCYCLIUM in?

HEXOCYCLIUM is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

HEXOCYCLIUM

AbbVie · FDA-approved approved Small molecule Quality 15/100

At a glance

Generic name	HEXOCYCLIUM
Sponsor	AbbVie
Drug class	hexocyclium
Target	Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved
First approval	1982

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HEXOCYCLIUM CI brief — competitive landscape report
HEXOCYCLIUM updates RSS · CI watch RSS
AbbVie portfolio CI